Abstract: An acylcyclohexadionethiocarboxylic S-ester of the fomrula ##STR1## where R.sup.1 and R.sup.2 are substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, benzyl or phenyl, and R.sup.2 is additionally hydrogen, are prepared by reacting an acylcyclohexadione II ##STR2## with hydroxylamine or hydroxylamine-O-sulfonic acid in an inert solvent at from 0.degree. to 150.degree. C., to give an acylcyclohexadione compound III ##STR3## and then reacting the compound III with a mercaptan IVR.sup.2 --SH IVin the presence of an anhydrous acid HX to give an acylcyclohexadionethiocarboximidic S-ester salt V ##STR4## where X is the anion of the acid, and hydrolyzing the compounds V to the acylcyclohexadionethiocarboxylic S-ester I.

Abstract: Disclosed herein are /.sup.35 S/-labelled compound of the formula (I):(C.sub.6 H.sub.5).sub.3 C.sup.35 SHand processes therefor. This Compound (I) is useful as an intermediate for the introduction of sulfur isotope into a variety of compounds. For example, it is useful in the introduction of sulfur isotope into important compounds such as 6-mercaptopurine, 5-[3-(2-(7-chloroquinolin-2-yl)ethenyl)phenyl]-8-dimethylcarbamyl-4,6-dith ioactanoic acid, a potent antagonist of leukotriene D.sub.4 ; thiophosphoric acid derivatives, photo-affinity reagents and the like.

Abstract: Trimethylsulfonium halides are made by reacting dimethyl sulfide and a methyl halide in the presence of a solvent mixture which includes water and a water-immiscible organic solvent. The organic water-immiscible solvent is generally present in an amount which is at least 40% but no more than 95% of the total solvent mixture. The reaction is preferably conducted under pressure.

Abstract: The color and odor of n-dodecyl mercaptoethanol made using a triethylamine catalyst are improved by contacting crude n-dodecyl mercaptoethanol with a polar organic solvent having a boiling point of within about .+-.15.degree. C. of the boiling point of triethylamine and heating said components under at least a partial vacuum.

Abstract: A 1-cyclohexyl-1-methylethyl peroxy ester, a novel compound, represented by the formula: ##STR1## wherein R.sup.1 stands for one member selected from the group consisting of H and alkyl groups and R.sup.2 and R.sup.3 independently stand for an alkyl group, provided that R.sup.2 and R.sup.3 each stand for an alkyl group of 1 to 5 carbon atoms and the sum of the carbon atoms of R.sup.2 and R.sup.3 is in the range of from 2 to 6 where R.sup.1 is H and R.sup.1, R.sup.2, and R.sup.3 each stand for an alkyl group of 1 to 9 carbon atoms and the sum of the carbon atoms of R.sup.1, R.sup.2, and R.sup.3 is in the range of from 3 to 11 where R.sup.1 is an alkyl group, a polymerization initiator for a vinyl group-containing compound monomer and a curing agent for an unsaturated polyester resin, which polymerization initiator and curing agent both contain as an active component thereof the ester mentioned above.

Abstract: 1,2,4-Oxadiazole and 1,2,4-thiadiazole derivatives of the fenamic acids, in which the fenamate residue is present at the 3-position of the 1,2,4-oxadiazole or 1,2,4-thiadiazole, pharmaceutically acceptable acid addition or base salts and methods of preparation for such compounds as well as pharmaceutical compositions alone or in combination with a second active ingredient are described. The compounds are active as inhibitors of cyclooxygenase and/or 5-lipoxygenase thereby providing methods of treatment for antiinflammatory diseases.

Abstract: Hemiketals and hemithioketals are produced by bringing into reactive contact an alcohol or mercaptan and an oxetan-2-one compound having the following structural formula: ##STR1## where Hal is a halogen.

Abstract: Isocyanatoalkyl sulphonates of the general formula ##STR1## wherein the substituent meanings are as given in the description are obtained by reacting the corresponding isocyanatoalkyl halides with sulphonic acid esters of the formula ##STR2## wherein R.sup.3 has the meanings given in the description. They are used as cross-linking agents in polyamines.

Abstract: Aryl ureas and carbamic acid derivatives of formulaA--NHCW--Y--Band pharmaceutically acceptable salts thereof whereinA is a specified aromatic radical including 3,5-dichlorophenylW is O or SY is NH or O andB is a specified saturated azacyclic ring, e.g. tropan-3-yl or quinuclidin-3-yl,possess 5-HT.sub.3 -antagonistic activity and are, for example, useful in treatment of migraine, emesis, anxiety, gastro-intestinal disorders and as anti-psychotics.

Abstract: The compound (3R, 4R)-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo[2.2.1]heptane and its salts behave as a functionally selective muscarinic agonist and are useful in the treatment of neurological and mental disorders, preferably in a pharmaceutical formulation comprising the active compound in association with a pharmaceutically acceptable carrier. The compound can be prepared by methods analogous to those known in the art via suitable chiral intermediates and cyclopropyl carboxamide oxime.

Abstract: A process for the separation of a compound comprising a 1,2-dihydroxycyclohexa-3,5-diene ring from a medium containing it in which the compound reacts with a phenylboronate ion to form a phenylboronate ester which is insoluble in the medium. Novel phenylboronate esters formed during the separation process are also claimed.

Abstract: Novel 1,6-diaza [4.4] spirodilactams having heterocyclic-containing substituents on each spiro ring nitrogen atom are produced by reaction of a heterocyclic-substituted primary amine compound and a spirodilactam precursor selected from 4-oxoheptanedioic acid compounds or 1,6-dioxaspiro[4.4]nonane-2,7-dione compounds. The substituted spirodilactam products have a plurality of heterocyclic rings and are useful in biological applications and as stabilizers.

Abstract: This invention relates to pyrrole derivatives of formula: ##STR1## in which A forms with the pyrrole ring an isoindoline, 6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine, 2,3,6,7-tetrahydro-5H-[1,4]oxathiino[2,3-c]pyrrole or 2,3,6,7-tetrahydro-5H-[1,4]dithiino[2,3-c]pyrrole ring-system and Hetis naphthyridinyl, pyridyl or quinolyl which is unsubstituted or substituted with halogen, (1 to 4 C) alkyl, (1 to 4 C) alkyloxy, (1 to 4 C) alkylthio or CF.sub.3 and R=(3 to 10 C) straight- or branched-chain alkenyl or alkyl which is unsubstituted or substituted with alkyloxy, alkylthio, (3 to 6 C) cycloalkyl, NH.sub.

Abstract: 2-Aminothiophenol is reacted with methyl (-)-(2R,3S)-2,3-epoxy-3-(4-methoxyphenyl)propionate, and the intermediate methyl (2S,3S)-3-[(2-aminophenyl)thio]-2-hydroxy-3-(4-methoxyphenyl)propionate is cyclized in the presence of methanesulfonic acid, in the same vessel and without isolating said intermediate product, using e.g. chlorobenzene as a solvent.

Abstract: Arylmethylazoles of the formula I ##STR1## in which Aryl is (substituted) phenyl or naphthyl;Z is CH or N;R.sup.1 and Q are H or alkyl;R.sup.2 is H, alk(en)yl or alkynyl;R.sup.3 and R.sup.4 are H, alkyl or other hydrocarbons; orR.sup.3 and R.sup.4 together are a--(CH.sub.2).sub.2-11 chain or a bridged--(CH.sub.2).sub.4-5 chain,and their acid addition salts, stereoisomers and optically active enantiomers possess outstanding antimycotic and antidepressant activity.They are obtained, inter alia, from arylmethylazoles II ##STR2## which are reacted with a strong base and then with a carbonyl compound III O.dbd.CR.sup.3 R.sup.4 ; thereafter, the product is reacted with the protic acid or with an alkyl halide IV R.sup.2 Hal.If desired, the products are converted to the acid addition salts, or the stereoisomers or optically active enantiomes are resolved.

Abstract: Disclosed are the pyrrolylphenyl-substituted hydroxamic acid derivatives of the formula ##STR1## wherein R represents hydrogen, lower alkyl, halogen or lower alkoxy; R.sub.1 and R.sub.2 independently represent hydrogen, lower alkyl or aryl; Y represents a direct bond, lower alkylene, lower alkenylene, lower alkadienylene, (thio, sulfinyl or sulfonyl)-lower alkylene or oxy-lower alkylene; Z represents ##STR2## wherein R.sub.3 represents hydrogen or acyl; R.sub.4 represents lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl, aryl or aryl-lower alkyl; or Z represents ##STR3## wherein R.sub.3 represents hydrogen or acyl; R.sub.5 represents lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl, aryl, aryl-lower alkyl, amino or N-(mono- or di-lower alkyl)-amino; R.sub.6 and R.sub.7 represent hydrogen or lower alkyl; and pharmaceutically acceptable salts thereof provided that R.sub.

Abstract: 4-Halogeno-2-alkoxyimino-3-oxo fatty acid can be produced by one-pot and one-step by reacting a halogenating agent with a 2-alkoxyimino-3-oxo fatty acid ester in an ether solvent or a mixed solvent of an ether solvent and an inert organic solvent such as carbon tetrachloride, benzene, toluene, etc.

Abstract: A dicyanopyrazine compound of the formula: ##STR1## wherein each of R.sub.1, R.sub.2 and R.sub.3 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aralkyl, substituted aralkyl or thienylmethyl, provided that R.sub.1, R.sub.2 and R.sub.3 are not simultaneously hydrogen and that at least one of R.sub.1, R.sub.2 and R.sub.3 is an alkyl group having four or more carbon atoms.

Abstract: The S-[d-2-(6-methoxy-2-naphthyl)-propionyl]d-2-mercaptopropionamidoacetic acid having formula: ##STR1## has improved therapeutic properties not only in comparison with the starting active principle, namely Naproxen, but also with respect to the corresponding racemic derivative, namely the (d,l) compound.

Abstract: Formamidine compounds of general formula I ##STR1## in which: R.sub.1 represents H or C.sub.1-4 alkyl,R.sub.2 represents benzoyl, benzyl, or alpha-hydroxybenzyl, the aromatic ring being optionally substituted by a halogen atom,R.sub.3 and R.sub.4, which are identical or different, represent hydrogen, lower-alkyl, or lower-alkenyl, or form between them with the formamidine function a heterocycle,R.sub.5 represents hydrogen or C.sub.1-4 lower-alkyl or forms with R.sub.4 a double bond (--N.dbd.R.sub.4) in the case of pseudoaromatic heterocycles,n equals 0 or 1,A represents a linear or branched C.sub.1-4 alkylene chain,X represents hydrogen, halogen, C.sub.1-4 lower-alkyl, C.sub.1-4 lower-alkoxy, or nitro, and pharmaceutically-acceptable salts thereof, are disclosed.The compounds and pharmaceutical compositions thereof are used, optionally in combination with other active principles, as drugs for the treatment of gastrointestinal ailments, especially as gastric antisecretory and antiulcer agents.